Drug combo shows promise for tough head and neck cancers
NCT ID NCT03691714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested two drugs—durvalumab and cetuximab—together in 35 people with head and neck cancer that had come back or spread and was no longer responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complete, and results help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab and cetuximab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with head and neck cancer that has returned or spread.
- What could go wrong
- This is a small, early-phase study (35 people) with no control group. The combination may cause serious side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UC Health
Cincinnati, Ohio, 45219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Tissue analysis may guide personalized cancer therapy
- Exercise after cancer therapy: a new way to gauge prognosis?